“I believe the benefits associated with the drug justify the risks. The benefits are real. When you have 40% of the patients who previously depended on red blood cell transfusions who no longer need transfusions, and this outcome lasts for an average of one year, I think that’s a significant benefit,” said Mikkael Sekeres, M.D., chief of the Division of Hematology at Sylvester Comprehensive Cancer Center.